KA-3001 / KYinno - LARVOL DELTA

The bispecific antibody KA-3001, targeting PSMA and CD28, specifically enhances T cell activation within prostate tumors (AACR 2024) - "In comparison to REGN5678, KA-3001 exhibits significantly stronger binding to PSMA-expressing prostate tumor cells, along with relatively lower CD28 activation, minimizing toxicity while maintaining anti-tumor efficacy. The BsAb demonstrates neither aggregation nor degradation. In conclusion, the BsAb KA-3001, developed using our common light chain antibody discovery platform, stands out as a promising pre-clinical candidate drug for the treatment of prostate cancer."

IO biomarker • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor